Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (191-200 of 397) with videos related to

Pageof 40
Sort By:
Casopis Lekaru Ceskych|April 8, 1977
[Results and possibilities of clinical cytogenetics in the Czech Socialist Republic (author's transl)]M Vrba, R Adámek, P Balícek, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
Advanced Electronic Materials|February 2, 2018
Polymorphism in the 1:1 Charge-Transfer Complex DBTTF-TCNQ and Its Effects on Optical and Electronic PropertiesKatelyn P Goetz, Jun'ya Tsutsumi, Sujitra Pookpanratana, et al.
NPJ Breast Cancer|December 28, 2018
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacyAngelo Di Leo, Joyce O'Shaughnessy, George W Sledge, et al.
Plos One|July 21, 2012
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trialShernan G Holtan, Preston D Steen, Nathan R Foster, et al.
Frontiers in Oncology|March 27, 2025
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b studySara M Tolaney, Komal Jhaveri, Teresa Helsten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 25, 2025
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social supportRyan Brown, Katie E Smith, Mohamed M Shanshal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Coprescription of tamoxifen and medications that inhibit CYP2D6Kostandinos Sideras, James N Ingle, Matthew M Ames, et al.
Mayo Clinic Proceedings|September 7, 2007
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerationsSandhya Pruthi, Judy C Boughey, Kathleen R Brandt, et al.
Molecular Endocrinology (Baltimore, Md.)|February 12, 2016
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator RegulationMing-Fen Ho, Tim Bongartz, Mohan Liu, et al.
Pageof 40

Showing results (191-200 of 397) with videos related to

Sort By:
Pageof 40
Casopis Lekaru Ceskych|April 8, 1977
[Results and possibilities of clinical cytogenetics in the Czech Socialist Republic (author's transl)]M Vrba, R Adámek, P Balícek, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
Advanced Electronic Materials|February 2, 2018
Polymorphism in the 1:1 Charge-Transfer Complex DBTTF-TCNQ and Its Effects on Optical and Electronic PropertiesKatelyn P Goetz, Jun'ya Tsutsumi, Sujitra Pookpanratana, et al.
NPJ Breast Cancer|December 28, 2018
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacyAngelo Di Leo, Joyce O'Shaughnessy, George W Sledge, et al.
Plos One|July 21, 2012
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trialShernan G Holtan, Preston D Steen, Nathan R Foster, et al.
Frontiers in Oncology|March 27, 2025
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b studySara M Tolaney, Komal Jhaveri, Teresa Helsten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 25, 2025
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social supportRyan Brown, Katie E Smith, Mohamed M Shanshal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Coprescription of tamoxifen and medications that inhibit CYP2D6Kostandinos Sideras, James N Ingle, Matthew M Ames, et al.
Mayo Clinic Proceedings|September 7, 2007
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerationsSandhya Pruthi, Judy C Boughey, Kathleen R Brandt, et al.
Molecular Endocrinology (Baltimore, Md.)|February 12, 2016
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator RegulationMing-Fen Ho, Tim Bongartz, Mohan Liu, et al.
Pageof 40